🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 59 of 757 · Phase 3 first, then by program name

  1. Futibatinib, FULVESTRANT

    Taiho Pharma Netherlands B.V.

    Malignant Solid Tumors

    phase 3 small molecule active

    1 trial

  2. G-Pen

    Xeris Biopharma Holdings

    Insulin Hypoglycemia

    phase 3 small molecule completed

    1 trial

  3. G-Pen

    INTEGRATED BIOPHARMA INC

    Insulin Hypoglycemia

    phase 3 small molecule completed

    1 trial

  4. G-Pen (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 3 small molecule completed

    1 trial

  5. G-SCF

    First Tracks Biotherapeutics

    Granulocyte Colony-stimulating Factor

    phase 3 small molecule active

    1 trial

  6. GA 20 mg/mL

    Teva Pharma GmbH

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  7. GA-GCB (velaglucerase alfa)

    Takeda Pharmaceuticals International AG

    Gaucher Disease

    phase 3 mab completed

    1 trial

  8. GABITRIL (tiagabine hydrochloride; CEP-6671)

    Teva Pharma GmbH

    General Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  9. GALLIUM (68GA) CHLORIDE, TILMANOCEPT

    Disc Medicine

    Endometrial cancer, uterine cancer

    phase 3 small molecule active

    1 trial

  10. GALLIUM (68GA) CHLORIDE, TILMANOCEPT

    Disc Medicine

    Carcinoma of the parotid gland

    phase 3 small molecule active

    1 trial

  11. GALLIUM (68GA) GOZETOTIDE , Zr-DFO-girentuximab, Gallium (68Ga) PSMA-11 (gozetotide) prepared using PSMA-11 Sterile Cold Kit

    Disc Medicine

    Metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  12. GB-0895

    Generate Biomedicines

    Severe Asthma

    phase 3 small molecule active

    2 trials

  13. GC4419 90mg

    Galera Therapeutics

    Oral Mucositis

    phase 3 small molecule completed

    1 trial

  14. GEMCI-cell® 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Gemcitabine 1 g Powder for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Carbomedac® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusio

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  15. GEMCITABINE , CARBOPLATIN , MIRVETUXIMAB SORAVTANSINE, TOPOTECAN , LY4170156, BEVACIZUMAB , PACLITAXEL , DOXORUBICIN

    Eli Lilly Co.

    Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  16. GEMCITABINE , JNJ-17000139, MITOMYCIN

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  17. GEMCITABINE , Tecentriq, PEMETREXED , VINORELBINE , CISPLATIN , DOCETAXEL , Tecentriq 1,200 mg concentrate for solution for infusion

    Roche Registration Limited

    Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. GEMCITABINE, GEMCITABINE, INFLIXIMAB, DURVALUMAB, MYCOPHENOLATE MOFETIL, CISPLATIN

    AstraZeneca AB

    Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder

    phase 3 small molecule active

    1 trial

  19. GEMCITABINE, INFLIXIMAB, CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, Rilvegostomig

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  20. GEMCITABINE, Mrtx1719 matching placebo, PACLITAXEL ALBUMIN-BOUND, MRTX1719

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  21. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  22. GENTAMICIN , CEFAZOLIN , VANCOMYCIN , TEDIZOLID , PRISTINAMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM , CEFOTAXIME, CEFTAROLINE FOSAMIL , AMOXICILLIN , OFLOXACIN , CLINDAMYCIN , TIGECYCLINE , LINEZOLID , AMIKACIN , LYMECYCLINE , CEFTRIAXONE , TEICOPLANIN , DOXYCYCLINE , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , Xydalba 500 mg powder for concentrate for solution for infusion, LEVOFLOXACIN , DELAFLOXACIN , CIPROFLOXACIN , CLOXACILLIN , OXACILLIN , DAPTOMYCIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , RIFAMP

    Pari Pharma GmbH

    Catheter related bloodstream infections due to Staphylococcus aureus

    phase 3 small molecule active

    1 trial

  23. GENTAMICINE PANPHARMA 80 mg, solution injectable, Gentamicin Placebo, Metronidazole Biogaran 500 mg Placebo, Natriumchlorid-Lösung 0,9 % Deltamedica, Injektionslösung, METRONIDAZOLE BIOGARAN 500 mg, comprimé pelliculé

    Pari Pharma GmbH

    Acute mesenteric ischemia

    phase 3 small molecule active

    1 trial

  24. GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources